Loncastuximab联合利妥昔单抗治疗初治不适合/虚弱老年弥漫大B细胞淋巴瘤
LOTIS-9为2期试验,评估Lonca-R方案治疗初治不适合(A组)或虚弱(B组)DLBCL患者。A组完全缓解率52.9%,B组41.7%,B组33.3%完成治疗。≥3级不良事件发生率75.6%,因毒性提前终止。
要点
- Lonca-R在虚弱/不适合初治DLBCL中显示有意义的疗效。
- A组CR率52.9%,B组CR率41.7%。
- ≥3级不良事件75.6%,因毒性提前终止。
核心结论
- Lonca-R在通常不符合临床试验或标准治疗条件的初治DLBCL患者中显示出有意义的疗效,但毒性导致试验提前终止。
研究设计与样本
- LOTIS-9为2期试验,纳入初治DLBCL患者,A组为不适合患者(n=17),B组为虚弱伴或不伴心脏合并症患者(n=24)。
- 治疗方案为Lonca(第1-2周期150 µg/kg,后续周期75 µg/kg)联合利妥昔单抗375 mg/m2静脉注射,每3周一次,共3-6周期,第3周期后根据疗效调整。
主要发现
- A组中位年龄84岁(范围80-91),B组80岁(范围67-92)。
- A组完全缓解率为52.9%(9/17),B组为41.7%(10/24)。
- B组中8例(33.3%)患者按方案完成治疗。
- ≥3级不良事件发生于31例(75.6%)患者,包括11例致死性事件。
临床怎么用
- Lonca-R可作为不适合或虚弱初治DLBCL患者的潜在靶向治疗选择,但需密切监测毒性。
- 因毒性问题,该方案在此类脆弱人群中的应用需谨慎评估风险获益。
局限性
- 试验因毒性关注而自愿提前终止。
- 样本量小(A组17例,B组24例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diffuse large B-cell lymphoma (DLBCL) therapy is typically treated with multi-agent chemotherapy with curative intent but is often challenging or poorly tolerated in patients who are elderly, frail, or have significant comorbidities. LOTIS-9 was a phase 2 trial of loncastuximab tesirine (loncastuximab tesirine-lpyl [Lonca]) plus rituximab (Lonca-R) in patients with newly diagnosed DLBCL who were unfit (cohort A) or frail with or without cardiac comorbidities (cohort B), the majority of whom typically would be ineligible for trials. Patients received Lonca (150 µg/kg during cycles 1-2, 75 µg/kg for subsequent cycles) and R (375 mg/m2) intravenously Q3W for 3-6 cycles, adapted based on response after cycle 3. The primary endpoint of cohort A was complete response (CR) rate; coprimary endpoints of cohort B were CR rate and proportion of patients who completed treatment per protocol. The median age was 84 years (range, 80-91) in cohort A (n=17) and 80 years (range, 67-92) in cohort B (n=24). The CR rates were 52.9% (A: 9/17) and 41.7% (B: 10/24), respectively. In cohort B, 8 (33.3%) patients completed treatment. Grade ≥3 adverse events occurred in 31 (75.6%) patients, including 11 fatal events. Due to toxicity concerns in this medically fragile population, LOTIS-9 was voluntarily terminated prematurely though meaningful efficacy was demonstrated in patients who typically would be ineligible for clinical trials and/or standard of care therapies. These findings provide important insights for future trials. Additional investigation of targeted therapies in vulnerable unfit and frail patients with DLBCL is warranted. (ClinicalTrials.gov Identifier: NCT05144009).
引用
- Nair R, Kumar A, Chapman AE, et al. Loncastuximab and Rituximab in Elderly Unfit/Frail Patients With Previously Untreated Diffuse Large B-Cell Lymphoma. Blood Adv. 2026. PMID: 42879743. doi:10.1182/bloodadvances.2026020494
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。